As we know, AChE and toxic Aβ are the main medication targets for treating AD so far, so dual binding AChE inhibitors [11], which can not only facilitate cholinergic transmission but also interfere with AD pathogenesis [12,13], namely the synthesis, deposition and aggregation of toxic Aβ in brain areas, have become the leading strategy for the development of anti-AD agents [14,15,16,17]. The gene discussed is ACHE; the disease is Alzheimer disease.